PIKTOR Hits 33% Confirmed Response Rate in Advanced Endometrial Cancer Phase 2
FTH has more than doubled off its 52-week low of $7.45.
Summary
Faeth's lead program PIKTOR, an all-oral serabelisib plus sapanisertib combination given with paclitaxel, produced a 33% confirmed objective response rate (12 of 36 evaluable patients) in advanced endometrioid endometrial cancer patients with PAM pathway mutations who had already failed a median of two prior lines of therapy. The PIK3CA-mutant subgroup did better at 44% (7 of 16), and preliminary median progression-free survival came in at 7.4 months with a 62% six-month PFS rate. Management argues that compares favorably to the 3-4 months typical of salvage chemotherapy and the 6-7 months seen with newer TOPO1-based ADCs, though this is a single-arm study that cannot prove comparative benefit. Safety looks manageable for the population: 64% had grade 3 or higher treatment-related events, neutropenia was the most common at 26% grade 3+, hyperglycemia and stomatitis were mostly low grade, and only 5% discontinued for toxicity with no treatment-related deaths. This follows the August FDA Fast Track designation for the same PIKTOR-plus-paclitaxel regimen and lands a week after Q3 results showed a $20.4 million quarterly loss against $174.8 million in cash that management says funds both PIKTOR trials to topline. The company now says it plans to move toward Phase 3 subject to regulatory alignment; the 8:00 a.m. ET webcast today is the first chance for questions on trial design and timing.
At the time of this announcement, FTH was trading at $22.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $569.9M. The 52-week trading range was $7.45 to $42.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.